Brief: Hepion Pharmaceuticals Completes 75 Mg Crv431 Dosing, Initiates 225 Mg Dosing In Phase 2A 'Ambition' Clinical Trial For Nash
10/12/2020 17:53
Dec 10 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS COMPLETES 75 MG CRV431 DOSING,
INITIATES
225 MG DOSING IN PHASE 2A 'AMBITION' CLINICAL TRIAL FOR NASH
Source text - https://bit.ly/3n1C3HU
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement